Top-News

Regenerx Biopharmaceuticals News

Keine aktuellen Kursdaten verfügbar
WKN: 875295
ISIN: US75886X1081
Typ: Aktie

Regenerx Biopharmaceuticals News

15.08.23 - PR Newswire
RegeneRx Effects Reverse Stock Split and Terminates SEC Reporting Obligations
RegeneRx Effects Reverse Stock Split and Terminates SEC Reporting Obligations PR Newswire
07.08.23 - PR Newswire
RegeneRx Receives Stockholder Approval for Reverse Stock Split
RegeneRx Receives Stockholder Approval for Reverse Stock Split PR Newswire
01.08.23 - PR Newswire
RegeneRx To Extend Consent Solicitation Vote
RegeneRx To Extend Consent Solicitation Vote PR Newswire
13.04.23 - PR Newswire
First Patient Enrolled into U.S. Phase 3 Neurotrophic Keratitis Clinical Trial with RGN-259
First Patient Enrolled into U.S. Phase 3 Neurotrophic Keratitis Clinical Trial with RGN-259 PR Newswire
11.04.23 - PR Newswire
RegeneRx Issues Letter To Stockholders
RegeneRx Issues Letter To Stockholders PR Newswire
31.01.23 - PR Newswire
Thymosin Beta 4 Research Leads Toward Potential Future Anti-aging Therapy
Thymosin Beta 4 Research Leads Toward Potential Future Anti-​aging Therapy PR Newswire
03.01.23 - PR Newswire
Publication of RGN-259 Phase 3 Clinical Trial Results in Patients with Neurotrophic Keratopathy
Publication of RGN-259 Phase 3 Clinical Trial Results in Patients with Neurotrophic Keratopathy PR Newswire
24.10.22 - PR Newswire
RegeneRx Licensee Submits Special Protocol Assessment to FDA for 4th Phase 3 Clinical Trial for Dry Eye Disease
RegeneRx Licensee Submits Special Protocol Assessment to FDA for 4th Phase 3 Clinical Trial for Dry Eye Disease PR Newswire
27.09.22 - PR Newswire
RegeneRx Partner Submits Phase 3 Protocol for Neurotrophic Keratopathy (NK)
RegeneRx Partner Submits Phase 3 Protocol for Neurotrophic Keratopathy (NK) PR Newswire
22.08.22 - PR Newswire
RegeneRx Issues 2022 Letter To Stockholders
RegeneRx Issues 2022 Letter To Stockholders PR Newswire
18.07.22 - PR Newswire
RegeneRx Partner Signs LOI with Global Ophthalmology CRO for Two Phase 3 Clinical Trials in Neurotrophic Keratitis
RegeneRx Partner Signs LOI with Global Ophthalmology CRO for Two Phase 3 Clinical Trials in Neurotrophic Keratitis PR Newswire
22.06.22 - PR Newswire
RegeneRx Licensee to Expand Phase 3 Clinical Trial Program with RGN-259
RegeneRx Licensee to Expand Phase 3 Clinical Trial Program with RGN-259 PR Newswire
04.05.22 - PR Newswire
Tβ4 Shows Potential as a Combination Treatment for Diabetes-Induced Complications of the Cornea
Tβ4 Shows Potential as a Combination Treatment for Diabetes-​Induced Complications of the Cornea PR Newswire
02.03.22 - PR Newswire
RegeneRx Provides Regulatory Update Regarding RGN-259
RegeneRx Provides Regulatory Update Regarding RGN-259 PR Newswire
11.02.22 - PR Newswire
RegeneRx Consultant to Receive Prestigious Award for Contributions in Field of Health
RegeneRx Consultant to Receive Prestigious Award for Contributions in Field of Health PR Newswire
25.01.22 - PR Newswire
Researchers Confirm Thymosin Beta 4's Ability to Protect Eyes From Ethanol Injury
Researchers Confirm Thymosin Beta 4's Ability to Protect Eyes From Ethanol Injury PR Newswire
12.01.22 - PR Newswire
RegeneRx Publishes Regulatory Update on RGN-259
RegeneRx Publishes Regulatory Update on RGN-259 PR Newswire
29.11.21 - PR Newswire
RegeneRx Joint Venture Requests Pre-BLA Meeting with FDA For RGN-259 for Dry Eye Syndrome
RegeneRx Joint Venture Requests Pre-BLA Meeting with FDA For RGN-259 for Dry Eye Syndrome PR Newswire
29.10.21 - PR Newswire
Clinical Results of RGN-259 for the Treatment of Neurotrophic Keratitis to be Presented at 2021 American Ophthalmology Association Meeting
Clinical Results of RGN-259 for the Treatment of Neurotrophic Keratitis to be Presented at 2021 American Ophthalmology Association Meeting PR Newswire
05.10.21 - PR Newswire
New Research Demonstrates Thymosin Beta 4's Potential Positive Effects on Alzheimer's Disease
New Research Demonstrates Thymosin Beta 4's Potential Positive Effects on Alzheimer's Disease PR Newswire

Newssuche

Videos

newspaper
18.04.24
Technical Trading: Gold mit weiterem Potenzial
Gold Long Typ: Turbo Open End WKN: UH4MU6 Hebel: 4,67 Laufzeit: OpenEnd Einstieg: Market ... Mehr »